|
Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study. |
|
|
Honoraria - Boehringer Ingelheim; Takeda; Yuhan |
Research Funding - Janssen Research & Development |
|
|
Honoraria - Boehringer Ingelheim; MSD; Pfizer |
Travel, Accommodations, Expenses - MSD |
|
|
Consulting or Advisory Role - MSD |
Speakers' Bureau - Amgen; AstraZeneca; Janssen; MSD Oncology; Roche; Sanofi; Takeda |
Research Funding - Amgen (Inst); BeiGene (Inst); BMS Brazil (Inst); Debiopharm Group (Inst); Ipsen (Inst); Janssen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Amgen; Janssen |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Beigene; Ipsen; Merck Sharp & Dohme; Novartis; Pfizer |
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Janssen-Cilag (Inst); Johnson & Johnson (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); ROCHE (Inst); Viracta Therapeutics (Inst) |
|
|
Honoraria - AstraZeneca; MSD; Roche |
Research Funding - AstraZeneca; Janssen Oncology; MSD Oncology; Novartis |
Travel, Accommodations, Expenses - MSD |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Janssen; Merck Serono; Roche |
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen Oncology; Pfizer; Roche; Sanofi/Regeneron |
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; MSD Oncology; Roche |
|
|
Travel, Accommodations, Expenses - Roche |
|
|
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences; Daiichi Sankyo; EMD Serono; Genentech; Janssen; Lilly; Mirati Therapeutics; Novartis; Pfizer; Takeda |
Speakers' Bureau - Blueprint Medicines; Janssen; Mirati Therapeutics; Mirati Therapeutics; Takeda |
Research Funding - Tempus |
Travel, Accommodations, Expenses - Anheart Therapeutics |
|
|
No Relationships to Disclose |
|
|
Employment - AstraZeneca (I) |
Consulting or Advisory Role - Abbvie; AMGEN; AstraZeneca; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Ipsen; Janssen; LEO Pharma; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda |
Research Funding - AstraZeneca (Inst); BMS (Inst); MSDavenir (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Janssen Oncology; Janssen Oncology; Roche |
|
|
Consulting or Advisory Role - AbbVie; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; MSD; Novartis; Pfizer; Roche/Genentech |
Speakers' Bureau - Bristol-Myers Squibb; Lilly; MSD; Novartis; Roche/Genentech |
|
|
|
Stock and Other Ownership Interests - JJ Innovative Medicine |
|
|
|
Stock and Other Ownership Interests - JJ Innovative Medicine |
|
|
|
Stock and Other Ownership Interests - JJ Innovative Medicine |
|
|
|
Stock and Other Ownership Interests - JJ Innovative Medicine |
|
|
|
Stock and Other Ownership Interests - JJ Innovative Medicine |
|
|
|
Stock and Other Ownership Interests - JJ Innovative Medicine |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Foundation Medicine; Genentech; Regeneron; Tempus |
Research Funding - Janssen (Inst); Mirati Therapeutics (Inst) |